



Positive Quality Intervention: Ruxolitinib (Jakafi®) - Managing Myelofibrosis Patients

Description of PQI: Ruxolitinib is a selective JAK2 inhibitor used for the treatment of myelofibrosis (MF). This PQI will review the close monitoring of platelets required to ensure appropriate dose and avoid severe thrombocytopenia due to the therapy.

Background: Ruxolitinib is FDA approved for the treatment of intermediate or high-risk patients with MF. This includes patients with primary MF, post polycythemia vera MF, post-essential thrombocytopenia MF, steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older, and chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. Ruxolitinib is also indicated in polycythemia vera and graft-versus-host disease.

PQI Process: Pharmacy management of patients’ labs to ensure correct dosing of ruxolitinib can contribute to increased efficacy and decreased toxicity of the therapy. When receiving a new prescription for ruxolitinib:

- Review dosing
 - Dosing is based on baseline platelet count; platelet counts must be monitored throughout therapy

| Baseline Platelet Count | Ruxolitinib Dose |
|--------------------------------------|------------------|
| > 200 x 10 ⁹ cells/L | 20 mg BID |
| 100 to 200 x 10 ⁹ cells/L | 15 mg BID |
| 50 to 99 x 10 ⁹ cells/L | 5 mg BID |

- Check for drug-drug interactions
- Lab Monitoring
 - CBC/CMP - baseline, every 2-4 weeks until dose is stabilized, then as clinically indicated
 - Lipid panel - Baseline and 8-12 weeks after initiation
- Ensure the patient has follow up labs scheduled appropriately (see lab monitoring section)
 - Add reminders in pharmacy management software or EMR for follow-up on patient’s labs every 2-4 weeks until dose is stabilized (usually within 8 weeks)
- Refills will be filled only after
 - CBC has been checked
 - Platelet count has been evaluated for appropriateness of dose
- Dose Modifications
 - Do not adjust dose within the first 4 weeks, and no more than every 2 weeks thereafter
 - Dose may be increased by 5 mg BID increments to a max dose of 25 mg BID if
 - Failure to achieve a reduction from baseline spleen length of 50% or a 35% reduction in spleen volume as measured by CT or MRI
 - Platelet count is more than 125 x 10⁹ cells/L at treatment week 4 and platelet count is never less than 100 x 10⁹ cells/L
 - ANC more than 0.75 x 10⁹ cells/L

IMPORTANT NOTICE: NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional. *Updated 4.29.24*

- Discontinue ruxolitinib if spleen size reduction or symptom improvements not observed after 6 months of therapy
- When discontinuing therapy for any reason other than thrombocytopenia, consider gradually tapering dose by 5 mg twice daily each week

- Evaluate platelet count and **recommend the following dose adjustments to provider**

Baseline Platelet Count of 100 x 10⁹ cells/L or Higher¹

| Current Platelet Count | Dose Adjustment |
|---|---|
| 125 x 10 ⁹ cells/L or higher | No dose adjustment |
| 100-124 x 10 ⁹ cells/L | If starting dose was 20 mg BID, decrease dose by 5 mg BID If starting dose was 15 mg BID or less, no adjustment needed |
| 75-99 x 10 ⁹ cells/L | Decrease dose to 10 mg BID If starting dose was 10 mg BID or less, no adjustment needed |
| 50-74 x 10 ⁹ cells/L | Decrease to 5 mg BID If starting dose was 5 mg BID, no adjustment needed |
| <50 x 10 ⁹ cells/L | Hold; restart when platelets >50 x 10 ⁹ cells/L |

Baseline Platelet Count of 50 to 99 x 10⁹ cells/L¹

| Current Platelet Count | Dose Adjustment |
|--|---|
| 25-35 x 10 ⁹ cells/L and platelet decline during prior 4 weeks is less than 20% | Decrease total daily dose by 5 mg For patients on 5 mg once daily prior to decline, continue same dose |
| 25-35 x 10 ⁹ cells/L and platelet decline during prior 4 weeks is 20% or higher | Decrease dose to 5 mg BID If dose is 5 mg BID, decrease to 5 mg once daily If dose is 5 mg once daily, continue same dose |
| < 25 x 10 ⁹ cells/L | Hold therapy; restart when platelets >35 x 10 ⁹ cells/L starting with 5 mg BID less than previous dose |

Patient-Centered Activities:

- Provide [Oral Chemotherapy Education \(OCE\)](#) sheet
- Reinforce importance of adherence
 - The only way to achieve the proper patient-specific dose is if the patient is adherent
- Schedule follow-up calls and laboratory monitoring
 - Educate the patient to the possibility of dose adjustments based on labs
- Monitoring skin at baseline and have the patient make note of any new lesions that arise

References:

1. [Jakafi® \(ruxolitinib\) \[package insert\]](#).